Research programme: LRRK2 inhibitors - Halia Therapeutics
Latest Information Update: 12 Jul 2022
Price :
$50 *
At a glance
- Originator Halia Therapeutics
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
- Research Parkinson's disease
Most Recent Events
- 21 Jun 2022 Early research in Parkinson's disease in USA (unspecified route) before June 2022 (Halia Therapeutics pipeline, June 2022)
- 21 Jun 2022 Preclinical trials in Alzheimer's disease in USA (unspecified route) before June 2022 (Halia Therapeutics pipeline, June 2022)